Stock data
Tarsus Pharmaceuticals, Inc. (TARS)
Tarsus Pharmaceuticals, Inc. (TARS) reported revenue of US$451.36M and net income of -US$66.42M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$451.36M | — | -US$70.97M | -US$66.42M | — |
| 2024 | US$182.95M | — | -US$120.57M | -US$115.55M | — |
| 2023 | US$17.45M | — | -US$143.16M | -US$135.89M | — |
| 2022 | US$25.82M | — | -US$62.71M | -US$62.09M | — |
| 2021 | US$57.03M | — | -US$12.16M | -US$13.83M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$173.91M | -US$18.55M | — |
| 2026-03-31 | US$162.05M | -US$6.97M | — |
| 2025-12-31 | US$151.67M | -US$8.37M | — |
| 2025-09-30 | US$118.70M | -US$12.59M | — |
| 2025-06-30 | US$102.66M | -US$20.34M | — |
| 2025-03-31 | US$78.33M | -US$25.12M | — |
| 2024-12-31 | US$66.41M | -US$23.11M | — |
| 2024-09-30 | US$48.12M | -US$23.42M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.